Novo Nordisk Cuts 4,000 More Jobs; Sionna Halves Staff
The new layoff tracker shows major biotech employers still shedding staff in 2026, with Novo Nordisk making deep cuts and Sionna dramatically reducing headcount.
Fierce Biotech's layoff tracker for 2026 has logged fresh job cuts at two drug developers. Novo Nordisk revealed that it has let go of 4,000 more employees, adding to the company's previously reported workforce reductions. The new figure indicates that the Danish pharmaceutical giant is still in a cost-cutting phase.
In a separate entry, Sionna Therapeutics said it has halved its staff. The company, which focuses on cystic fibrosis treatments, appears to have made a sharp strategic pivot that resulted in a significant reduction in headcount. The two cases are unrelated but together signal that workforce contraction remains common across the biotech sector this year.
Fierce Biotech also asks readers to alert its editorial team about any layoffs not yet listed, meaning the tracker is expected to grow as more companies disclose staffing changes. As with any single source, these figures reflect only what the company announced and what the tracker has compiled so far.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.